14 reports

Report Scope: The key objectives of this study are to - Review the impact that diabetes is having on global health. This includes - - Review of diabetes as a disease. - Review of the epidemiology of diabetes. - Data and statistics by region. - Predictions of future incidence and prevalence of diabetes...

  • Antidiabetics
  • Medical Device
  • Diabetes
  • World
  • Medical Devices Sales
  • Diabetes Prevalence

Major players in the insulin drugs market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, and NovoRapid/Novolog. The global insulin drugs market is expected to grow from $25.88 in billion 2020 to $27.2 billion in 2021 at a compound annual growth rate (CAGR) of 5.1%.The growth is mainly due to...

  • Insulin
  • Diabetes
  • World
  • United States
  • APAC
  • United Kingdom
  • Diabetes Prevalence
  • Labour Utilisation

Major players in the market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, NovoRapid/Novolog, Actrapid, Admelog, Novolin/Actrapid/Insulatard, Ryzodeg, Sanofi, Soliqua/Suliqua, Toujeo, Tresiba and Xultophy. The global insulin drugs market is expected to grow from $28.82 in billion 2021 to $32.51...

  • Insulin
  • Diabetes
  • World
  • United States
  • Middle East
  • India
  • APAC
  • United Kingdom
  • Diabetes Prevalence
  • Labour Utilisation

This study covers the world outlook for insulins and anti-diabetic hormones and synthetic substitute pharmaceuticals across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country...

  • Antidiabetics
  • Insulin
  • World
  • United States
  • Disposable Income
  • Gross Domestic Product

This study covers the world outlook for antidiabetics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative...

  • Antidiabetics
  • World
  • Gross Domestic Product
  • Disposable Income

This study covers the latent demand outlook for insulins and anti-diabetic hormones and synthetic substitute pharmaceuticals across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each...

  • Antidiabetics
  • Insulin
  • United States
  • Disposable Income
  • Purchasing Power Parity

This study covers the latent demand outlook for insulins and anti-diabetic hormones and synthetic substitute pharmaceuticals across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city...

  • Antidiabetics
  • Insulin
  • India
  • Disposable Income
  • Purchasing Power Parity

This study covers the latent demand outlook for insulins and anti-diabetic hormones and synthetic substitute pharmaceuticals across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions...

  • Antidiabetics
  • Insulin
  • China
  • Disposable Income
  • Purchasing Power Parity

Are novel therapies set to revolutionise NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but this could all change in the next 3-5 years. Four late-stage pipeline programmes are advancing through development, and 16 mid-stage pipeline programmes are also making progress. Which ones will...

  • Hormone
  • Digestive System Disorder
  • Antidiabetics
  • Specialty Hospital
  • United States

“US Antidiabetics Drug Market Outlook 2022” report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology ( Prevalence of Type 1 & 2 Diabetes) in the US market along with the associated economic burden and productivity loss. Diabetes...

  • Antidiabetics
  • Diabetes
  • Insulin
  • United States
  • Diabetes Prevalence

Use this report to: - Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole - Identify important trends and provide sales forecasts by product categories and major country markets through 2021 - Study epidemiological data, projections and information on R&D trends, and...

  • Diabetes
  • Healthcare
  • Antidiabetics
  • World

Global antidiabetics market is expected to reach USD 84.13 billion by 2020. Growing prevalence of diabetes is the primary driver of this market. Growth in prevalence of disease causing lifestyle disorders such as irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases....

  • Antidiabetics
  • World
  • APAC
  • Diabetes Prevalence
  • Fuel Price

The medium term: battle lines are drawn The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both established and emerging markets have seen the sector return a 5 year compound...

  • Diabetes
  • Insulin
  • United States

Abstract Diabetes is a metabolic disorder arising mainly due to the fault in the production of insulin or mounting resistance to its action. In the case of Diabetes, the most serious problem is the side effect, which occurs due to the accumulation of glucose. This excess glucose is converted into various compounds and also into...

  • Spice
  • Insulin
  • Diabetes
  • Healthcare
  • World
  • United States
  • Diabetes Prevalence
  • Health Expenditure